Oakmont Investment Advisors Inc. Takes Position in Novo Nordisk A/S $NVO

Oakmont Investment Advisors Inc. purchased a new stake in Novo Nordisk A/S (NYSE:NVO) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 24,243 shares of the company’s stock, valued at approximately $1,162,000.

A number of other hedge funds also recently bought and sold shares of NVO. Godfrey Financial Associates Inc. purchased a new position in shares of Novo Nordisk A/S during the 4th quarter valued at approximately $25,000. Scarborough Advisors LLC purchased a new stake in Novo Nordisk A/S in the 1st quarter worth $26,000. Transamerica Financial Advisors LLC increased its holdings in Novo Nordisk A/S by 201.5% in the 4th quarter. Transamerica Financial Advisors LLC now owns 603 shares of the company’s stock worth $31,000 after acquiring an additional 403 shares in the last quarter. Johnson Financial Group Inc. raised its position in Novo Nordisk A/S by 128.0% during the third quarter. Johnson Financial Group Inc. now owns 684 shares of the company’s stock worth $38,000 after acquiring an additional 384 shares during the period. Finally, Continuum Advisory LLC acquired a new position in Novo Nordisk A/S during the second quarter worth $38,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

NVO has been the topic of several research analyst reports. Nordea Equity Research upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Deutsche Bank Aktiengesellschaft downgraded shares of Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research report on Thursday, August 27th. Berenberg Bank set a $47.00 price objective on Novo Nordisk A/S in a report on Wednesday, August 12th. HSBC reiterated a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, July 6th. Finally, Zacks Research raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. Four research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Hold” and a consensus target price of $64.94.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $46.59 on Friday. The company has a market cap of $208.02 billion, a P/E ratio of 11.39, a P/E/G ratio of 1.60 and a beta of 0.74. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $64.16. The company’s 50-day moving average price is $47.93 and its 200-day moving average price is $43.79. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. The company had revenue of $11.98 billion during the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 61.20%. On average, sell-side analysts forecast that Novo Nordisk A/S will post 3.45 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently disclosed a dividend, which was paid on Tuesday, August 25th. Investors of record on Monday, August 17th were given a dividend of $0.5786 per share. The ex-dividend date was Monday, August 17th. This represents a yield of 258.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 20.05%.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.